BioCryst to explore oral liquid formulation of BCX7353 for use in Acute HAE attacks
Biocryst announced that it has received approvals from Europe's initial regulatory to explore a new Oral liquid formulation of BCX7353 for the treatment of Acute attacks in patients…
Read More...
Read More...
